- Home
- AGIO vs RXRX Comparison
AGIO vs RXRX Comparison
Compare AGIO & RXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGIO | RXRX |
|---|---|---|
| Founded | 2007 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | AGIO | RXRX |
|---|---|---|
| Price | $33.62 | $3.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $38.88 | $7.50 |
| AVG Volume (30 Days) | 777.0K | ★ 15.0M |
| Earning Date | 04-29-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 14.79 |
| EPS | N/A | ★ N/A |
| Revenue | $43,011,000.00 | ★ $74,681,000.00 |
| Revenue This Year | $76.75 | $12.11 |
| Revenue Next Year | $170.73 | $82.52 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 26.92 |
| 52 Week Low | $22.24 | $2.77 |
| 52 Week High | $46.00 | $7.18 |
Technical Indicators
Market Signals| Indicator | AGIO | RXRX |
|---|---|---|
| Relative Strength Index (RSI) | 48.19 | 44.50 |
| Support Level | $32.54 | $2.87 |
| Resistance Level | $36.04 | $4.03 |
| Average True Range (ATR) | 1.28 | 0.19 |
| MACD | 0.10 | -0.02 |
| Stochastic Oscillator | 42.77 | 8.33 |
Price Performance
Historical ComparisonAbout AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236 and others.
About RXRX Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc is a clinical-stage biotechnology company. The company is decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Geographically, the company operates in United States, United Kingdom, and Others. It derives maximum revenue from United States.